% | $
Quotes you view appear here for quick access.

RXi Pharmaceuticals Corporation Message Board

  • red900901 red900901 Apr 5, 2013 4:50 PM Flag

    "37% Average Reduction in Scar Tissue Observed - Exciting Scar Reduction Activity Observed in Two Phase 1 RXI-109 Clinical Studies"


    "During the recent 2013 BIO CEO Conference, which took place in New York City, RXi Pharmceuticals presented new exciting preliminary blinded data for RXI-109 from their scar prevention and reduction studies. Noticeable reductions in scar tissue were observed in two studies and there appears to be a clear correlation between CTGF expression and scar area, providing strong evidence of the mechanism of action."

    Source: lifesciadvisors.c*m/clientinfo/rxi/RXi__BIO_CEO_2-14-13__clientinfo.pdf

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.30+0.01(+3.59%)Feb 8 4:00 PMEST